Expert Opinion on Drug Metabolism & Toxicology最新文献_第2页

Optimizing co-prescription of clozapine and antiseizure medications: a systematic review and expert recommendations for clinical practice 优化氯氮平与抗癫痫药物的联合处方：系统综述与专家临床实践建议

IF 4.3 3区医学

Expert Opinion on Drug Metabolism & Toxicology Pub Date : 2024-04-13 DOI: 10.1080/17425255.2024.2343020

Hélène Verdoux, Clélia Quiles, Jose de Leon

引用次数: 0

Predicting drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors and forward planning 预测接受 CDK4/6 抑制剂治疗的乳腺癌患者的药物相互作用并制定前瞻性计划

IF 4.3 3区医学

Expert Opinion on Drug Metabolism & Toxicology Pub Date : 2024-04-11 DOI: 10.1080/17425255.2024.2341810

Abha Kulkarni, Jasmeet Singh

引用次数: 0

Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes: an update 降糖药物对 2 型糖尿病患者心血管预后的影响：最新进展

IF 4.3 3区医学

Expert Opinion on Drug Metabolism & Toxicology Pub Date : 2024-04-11 DOI: 10.1080/17425255.2024.2341882

Brian Tomlinson, Paul Chan

引用次数: 0

Adverse events related to drug-drug interactions in COVID-19 patients. A persistent concern in the post-pandemic era: a systematic review COVID-19患者中与药物相互作用相关的不良事件。后流行病时代持续存在的问题：系统综述

IF 4.3 3区医学

Expert Opinion on Drug Metabolism & Toxicology Pub Date : 2024-04-03 DOI: 10.1080/17425255.2024.2339397

Valeria Conti, Nicola Bertini, Rosaria Ricciardi, Berenice Stefanelli, Emanuela De Bellis, Carmine Sellitto, Marco Cascella, Francesco Sabbatino, Graziamaria Corbi, Pasquale Pagliano, Amelia Filippelli

引用次数: 0

Exploring the level of agreement among different drug-drug interaction checkers: a comparative study on direct oral anticoagulants 探索不同药物相互作用检查器之间的一致程度：关于直接口服抗凝剂的比较研究

IF 4.3 3区医学

Expert Opinion on Drug Metabolism & Toxicology Pub Date : 2024-02-22 DOI: 10.1080/17425255.2024.2322134

Massimo Carollo, Salvatore Crisafulli, Francesco Ciccimarra, Giuseppe Andò, Igor Diemberger, Gianluca Trifirò

引用次数: 0

Chronic kidney disease and physiologically based pharmacokinetic modeling: a critical review of existing models 慢性肾病和基于生理的药代动力学模型：对现有模型的批判性评述

IF 4.3 3区医学

Expert Opinion on Drug Metabolism & Toxicology Pub Date : 2024-01-25 DOI: 10.1080/17425255.2024.2311154

Ammara Zamir, Faleh Alqahtani, Muhammad Fawad Rasool

引用次数: 0

Overcoming barriers to machine learning applications in toxicity prediction 克服机器学习应用于毒性预测的障碍

IF 4.3 3区医学

Expert Opinion on Drug Metabolism & Toxicology Pub Date : 2023-12-13 DOI: 10.1080/17425255.2023.2294939

Abdallah Abou Hajal, Ahmad Z. Al Meslamani

引用次数: 0

Advances in the understanding of acetaminophen toxicity mechanisms: a clinical toxicology perspective. 对乙酰氨基酚毒性机制的理解进展：从临床毒理学角度。

IF 4.3 3区医学

Expert Opinion on Drug Metabolism & Toxicology Pub Date : 2023-09-01 Epub Date: 2023-09-15 DOI: 10.1080/17425255.2023.2259787

Angela L Chiew, Geoffrey K Isbister

{"title":"Advances in the understanding of acetaminophen toxicity mechanisms: a clinical toxicology perspective.","authors":"Angela L Chiew, Geoffrey K Isbister","doi":"10.1080/17425255.2023.2259787","DOIUrl":"10.1080/17425255.2023.2259787","url":null,"abstract":"Introduction: Acetaminophen (paracetamol) is a commonly used analgesic and antipyretic agent, which is safe in therapeutic doses. Acetaminophen poisoning due to self-harm or repeated supratherapeutic ingestion is a common cause of acute liver injury. Acetylcysteine has been a mainstay of treatment for acetaminophen poisoning for decades and is efficacious if administered early. However, treatment failures occur if administered late, in 'massive' overdoses or in high-risk patients.Areas covered: This review provides an overview of the mechanisms of toxicity of acetaminophen poisoning (metabolic and oxidative phase) and how this relates to the assessment and treatment of the acetaminophen poisoned patient. The review focuses on how these advances offer further insight into the utility of novel biomarkers and the role of proposed adjunct treatments.Expert opinion: Advances in our understanding of acetaminophen toxicity have allowed the development of novel biomarkers and a better understanding of how adjunct treatments may prevent acetaminophen toxicity. Newly proposed adjunct treatments like fomepizole are being increasingly used without robust clinical trials. Novel biomarkers (not yet clinically available) may provide better assessment of these newly proposed adjunct treatments, particularly in clinical trials. These advances in our understanding of acetaminophen toxicity and liver injury hold promise for improved diagnosis and treatment.","PeriodicalId":12250,"journal":{"name":"Expert Opinion on Drug Metabolism & Toxicology","volume":" ","pages":"601-616"},"PeriodicalIF":4.3,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10264116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Drug absorption from oral formulations in patients with short bowel syndrome: a comprehensive update of the literature. 短肠综合征患者口服制剂的药物吸收：文献的全面更新。

IF 4.3 3区医学

Expert Opinion on Drug Metabolism & Toxicology Pub Date : 2023-09-01 Epub Date: 2023-09-08 DOI: 10.1080/17425255.2023.2256216

Samuel Azuz, Jakob Lykke Poulsen, Lars Vinter-Jensen, Anne Estrup Olesen

{"title":"Drug absorption from oral formulations in patients with short bowel syndrome: a comprehensive update of the literature.","authors":"Samuel Azuz, Jakob Lykke Poulsen, Lars Vinter-Jensen, Anne Estrup Olesen","doi":"10.1080/17425255.2023.2256216","DOIUrl":"10.1080/17425255.2023.2256216","url":null,"abstract":"ABSTRACT Introduction Drug absorption is often altered and typically diminished in patients with short bowel syndrome (SBS). It is important to understand the patient’s gastrointestinal anatomy, the absorptive capacity of the remaining bowel, and the physicochemical and pharmacokinetic properties of the drug to optimize oral pharmacotherapy. Areas covered The primary focus was to provide an updated understanding of the absorption of various drugs in patients with short bowel syndrome. Forty-seven studies covering 13 different drug classes were included in the review and study details, patient characteristics, drug characteristics and pharmacokinetic findings were summarized for each drug class. Expert opinion Improving and simplifying drug treatment in patients with SBS have high priority, but the patients are multi diseased so knowledge regarding absorption of drugs as e.g. antithrombotic agents, immunosuppressants is urgently needed. Therefore, it is crucial to advance our understanding of the fundamental factors involved in drug absorption, spanning from drug design to pathophysiology. With the growing knowledge in drug design and gastrointestinal pathophysiology, we anticipate the development of computer models that can accurately predict optimal absorption in the future.","PeriodicalId":12250,"journal":{"name":"Expert Opinion on Drug Metabolism & Toxicology","volume":" ","pages":"577-600"},"PeriodicalIF":4.3,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10177283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Metabolic and toxicological considerations for phosphoinositide 3-kinase delta inhibitors in the treatment of chronic lymphocytic leukemia. 磷酸肌醇3-激酶δ抑制剂治疗慢性淋巴细胞白血病的代谢和毒理学考虑。

IF 4.3 3区医学

Expert Opinion on Drug Metabolism & Toxicology Pub Date : 2023-09-01 Epub Date: 2023-09-15 DOI: 10.1080/17425255.2023.2260305

Magdalena Witkowska, Agata Majchrzak, Paweł Robak, Anna Wolska-Washer, Tadeusz Robak

{"title":"Metabolic and toxicological considerations for phosphoinositide 3-kinase delta inhibitors in the treatment of chronic lymphocytic leukemia.","authors":"Magdalena Witkowska, Agata Majchrzak, Paweł Robak, Anna Wolska-Washer, Tadeusz Robak","doi":"10.1080/17425255.2023.2260305","DOIUrl":"10.1080/17425255.2023.2260305","url":null,"abstract":"Introduction: Phosphoinositide 3-kinase delta (PI3Kδ) inhibitors are a class of novel agents that are mainly used to treat B-cell malignancies. They function by inhibiting one or more enzymes which are part of the PI3K/AKT/mTOR pathway. Idelalisib is a first-in-class PI3Kδ inhibitor effective in patients with B-cell lymphoid malignancies.Areas covered: This article reviews the chemical structure, mechanism of action, and metabolic and toxicological properties of PI3Kδ inhibitors and discusses their clinical applications in monotherapy and in combination with other agents for the treatment of chronic lymphocytic leukemia (CLL). A search was conducted of PubMed, Web of Science, and Google Scholar for articles in English.Results/conclusion: PI3Kδ inhibitors hold potential for the treatment of B-cell malignancies, including CLL. However, their use is also associated with severe toxicities, including pneumonia, cytopenias, hepatitis, and rash. Newer drugs are in development to reduce toxicity with novel schedules and/or combinations.Expert opinion: The development of novel PI3Kδ inhibitors might help to reduce toxicity and improve efficacy in patients with CLL and other B-cell lymphoid malignancies.","PeriodicalId":12250,"journal":{"name":"Expert Opinion on Drug Metabolism & Toxicology","volume":" ","pages":"617-633"},"PeriodicalIF":4.3,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10610453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0